All News

Best of 2021: EULAR Guidelines on Intraarticular Therapy

Save

d Jack Cush, MD

Dec 20, 2021

EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.

Read Article

When to Stop Biologics in Systemic JIA?

Save

d Jack Cush, MD

Dec 13, 2021

Systemic onset juvenile idiopathic arthritis (sJIA) is a dramatic onset inflammatory condition marked by spiking fevers, intermittent rash, polyarthritis and a host of other hyperinflammatory manifestations.

Read Article

Genes and Obesity Tied to Higher Gout Risk in Women Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found. https://t.co/vLR8GJC9qf https://t.co/6Scc5c0dUU

Links:

https://bit.ly/3yomMYo

Dr. John Cush RheumNow ( View Tweet)

Dec 13, 2021

DORIS - Defining Remission in Lupus

Save

d Jack Cush, MD

Nov 29, 2021

Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE. A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016.

Read Article

Giant Cell Arteritis Novel Treatment Options

Save

d Richard Conway, MBBChBAO, PhD

Nov 29, 2021

Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.

Read Article

Long Term Steroid Use in RA - Matters of the Heart: Dr. Mrinalini Dey ( @DrMiniDey) discusses abstract #1428 presented at the #ACR21 annual meeting. https://t.co/E6RSlPAuRT https://t.co/QBhKD855aH

Links:

https://bit.ly/3FA3qle

Dr. John Cush RheumNow ( View Tweet)

Nov 22, 2021

GLORIA Study - Is Prednisone Harmful in Elder RA? The GLORIA study (ABST#1678) was a pragmatic, blinded placebo-controlled randomized trial where they assessed whether prednisolone (vs. placebo) use would alter clinical outcomes over 2 years. https://t.co/eKXjiDpHlc https://t.co/JtCgc1uZnE

Links:

https://bit.ly/3Fr8atf

Dr. John Cush RheumNow ( View Tweet)

Nov 19, 2021

Top vasculitis takeaways from ACR 2021

Save

d Janet Pope, MD, MPH, FRCPC

Nov 18, 2021

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis.

Read Article

GLORIA Study - Is Prednisone Harmful in Elder RA?

Save

d Jack Cush, MD

Nov 17, 2021

The GLORIA study (ABST# 1678) was a pragmatic, blinded placebo-controlled randomized trial from Dr. Martin Boers and colleagues where they assessed whether prednisolone (vs. placebo) use would alter clinical outcomes over 2 years.

Read Article

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Save

d Jack Cush, MD

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article

Emapalumab for the treatment of macrophage activation syndrome

Save

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

Nov 12, 2021

Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a potentially life-threatening complication of systemic inflammatory disorders, most commonly occurring in people with systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE).

Read Article

Another study linking long term GC and CV risk in RA! Medicare data >65yo 130000+ pts 1-year incidence CV ⬆️ as follows: 📍Dose ≤5mg 1.4% 📍Dose 5-10mg 1.7% 📍Dose >10mg 1.9% Not replicated in younger pts (Optum data) #ACR21 #Abst1915 @RheumNow https://t.co/DLXdfvfiBW

Aurelie Najm AurelieRheumo ( View Tweet)

Nov 09, 2021

Once again #steroids are bad in #RheumatoidArthritis from 2 large admin databases in age >65 in Medicare data, not in younger pts -Optum data. Clear dose response #ACR21 #ACRBest @RheumNow abst#1915 https://t.co/XL93jty7C9

Janet Pope Janetbirdope ( View Tweet)

Nov 09, 2021

#ACR21 Abs#1915 👉🏼Chronic steroid use in older adults on stable DMARD therapy assoc w/ ⬆️CV risk 👉🏼Risk even present among older adults receiving low dose ≤5mg/day 👉🏼Larger studies needed in younger healthier adults @RheumNow https://t.co/Lsj5YBz7IG

Mrinalini Dey DrMiniDey ( View Tweet)

Nov 09, 2021

Long-term low dose glucocorticoid use associated ⬆️cardiovascular risk. Clear effect in Medicare population (older), not evident in Optum (younger). Dose dependent. Abstr#1915 #ACR21 @RheumNow https://t.co/oFet3Hhsfo

Richard Conway RichardPAConway ( View Tweet)

Nov 09, 2021

Fibromyalgianess Glucocorticoid Persistence in RA Patients: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #0120 presented at the #ACR21 annual meeting. https://t.co/9yOM5rSARv https://t.co/Gq2YxbxkmM

Links:

https://bit.ly/3mU8Voe

Dr. John Cush RheumNow ( View Tweet)

Nov 09, 2021

Glory to GLORIA trial? Low dose prednisone 2mg in active RA>65yrs, N=451 All Standard care. in 2yrs, ~40% drop out- same in each grp Better RA control but NNH 9.5 w steroids, mostly non severe infections. So, prednisone debate in RA continues #ACR21 @RheumNow #ACRBest abst#1678 https://t.co/emOaYSjYAa

Janet Pope Janetbirdope ( View Tweet)

Nov 09, 2021

Sub-analysis of ICHIBAN study looking at adverse events in tocilizumab treated patients with/without steroids. Steroids associated with small increase in adverse events across board. Abstr#1693 #ACR21 @RheumNow https://t.co/ldiovirKpo

Richard Conway RichardPAConway ( View Tweet)

Nov 09, 2021

What is the effect of long-term #steroid use on major adverse #cardiovascular events (MACE)? Find out in my video summary of abstract #1428 which was presented yesterday by @BethIWallace Read here👉🏼https://t.co/fCM3m04ruS Watch here👉🏼https://t.co/TLerQT7XnG #ACR21 @RheumNow

Links: